ECC: T-DM1 May Be New Standard of Care in Heavily Pretreated Advanced Breast Cancer

T-DM1, a combination drug of trastuzumab and a cell-killing drug emtansine, significantly improved progression-free survival in women with advanced HER2-positive breast cancer whose cancer has recurred or progressed despite previous treatments, according to the results of the TH3RESA trial.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news